Tackling the big challenges in biomedical research is no longer the domain of a single discipline. Can immunity be used to target cancer? Do stem cells offer hope for treating asthma? Solutions don’t work in isolation and neither do we.
One in two men and one in three women will be diagnosed with cancer in their lifetime. Yet, there remains an unmet clinical need in treating cancers. We're combining efforts to close that gap, to understand the molecular basis of how cancers develop and progress.
The largest of the BDI programs with more than 50 group leaders, our collective expertise traverses microbial pathogenesis, proteomics, molecular imaging and a whole lot more to develop targeted treatments, immunotherapies and vaccines.
Regarded as the epidemic of the 21st century, we're unravelling the complexities of what causes metabolic diseases and obesity and how they contribute to other diseases such as type 2 diabetes and cancer.
By 2050, it's forecast 100 million of us will be living with Alzheimer's. So we're testing new treatments for neural dysfunction with a focus on pharmacology and the rapidly emerging field of Brain Computer Interfaces.